Indications

Indications

Our lead program is for treatment of inflammatory bowel disease (IBD), which is comprised of Crohn’s Disease (CD) and Ulcerative Colitis (UC). Artizan also has a paradigm-changing second program in Parkinson’s Disease.

Gastrointestinal / Immunology

IBD refers to a set of diseases that cause chronic inflammation of the small and/or large intestines with roughly 45% of cases defined as CD and 55% are UC.¹ As of 2017, the global prevalence of IBD is between 6-8 million cases², approximately 3 million of which are in the United States³. CD and UC can occur at any age, but diagnoses are most frequent between the ages of 15 and 35. IBD is a complex condition for which currently available therapies are only moderately effective, many patients fail to achieve a deep, long-lasting remission. While there have been tremendous advances in IBD therapies, approximately 30% of patients are unresponsive to initial biologics therapy and, even among responsive patients, up to 10% stop responding to treatment annually. For more information about IBD, please visit the Crohn’s & Colitis Foundation.

Neurodegenerative

More than 10 million people worldwide are living with PD Parkinson’s disease. (PD) is the second most common neurodegenerative disease in the United States, affecting an estimated 1 million people or ~1% of the entire US population. PD is a neurodegenerative amyloid disorder that causes unintended or uncontrollable movements of the body. While the precise cause of PD is unknown, some cases are thought to occur from a combination of genetics, immunologic, and environmental factors that trigger the disease. Studies have shown that signals from gut microbes are required for neuroinflammatory responses and promote a-synuclein-mediated motor deficits and brain pathology.¹ PD has no cure and current treatments help control symptoms, but do not address its root cause. For more information, please visit the Parkinson’s Foundation.